

Changed date for Interim Report

The board of Q-linea AB (publ) ("Q-linea" or the "Company") has decided to bring forward the date for the publication of the Interim Report for the first quarter to 14 April.

The decision to release the report earlier than previously announced is linked to the fact that the period for determining the subscription price for the series TO1 warrants occurs between 14 and 29 April. As the quarterly report for the first quarter of 2025 has been completed earlier than expected, and to ensure that the market has access to relevant and updated information during the described price setting period, the Board has deemed it most appropriate to advance the publication to 14 April 2025, at 07:30.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

[Changed date for Interim Report](#)